Selective BCL-2 inhibition by Venetoclax (VEN) is a successful therapeutic strategy in various lymphoid malignancies, including preclinical activity in BCP-ALL [7–12]. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.